November 19, 2010 --
Minneapolis and New York -- An implantable medical
device used in the minimally invasive treatment of thoracic
aortic aneurysms, the Valiant® Thoracic Stent Graft System
from Medtronic, Inc. (NYSE: MDT), delivered strong results
through 30 days of patient follow-up in the company’s U.S.
pivotal study, according to clinical data presented at VEITHsymposium™.
Approved by the U.S. Food and Drug Administration (FDA) under
an investigational device exemption (IDE), the prospective,
single-arm study involved 160 patients at 24 U.S. medical centers. |